312962-27-9

Upstream product

• 312962-23-5 2-allyl-6-methoxy-benzoic acid (1R,3S,4R)-1-[2-(4-methoxy-benzyloxy)-ethyl]-3-methoxymethoxy-4,7-dimethyl-oct-6-enyl ester 
• 303-07-1 2,6-Dihydroxybenzoic acid 
• 154714-19-9 5-hydroxy-2,2-dimethyl-4H-benzo[d][1,3]dioxin-4-one 
• 325172-41-6 (2R,3S,5S)-2-Allyl-5-(tert-butyl-dimethyl-silanyloxy)-1-((1S,5R,7R)-10,10-dimethyl-3,3-dioxo-3λ⁶-thia-4-aza-tricyclo[5.2.1.0^1,5]dec-4-yl)-7-(4-methoxy-benzyloxy)-3-methoxymethoxy-heptan-1-one 
• 325172-31-4 (2R,3S,5S)-2-Allyl-5-(tert-butyl-dimethyl-silanyloxy)-1-((1S,5R,7R)-10,10-dimethyl-3,3-dioxo-3λ⁶-thia-4-aza-tricyclo[5.2.1.0^1,5]dec-4-yl)-3-hydroxy-7-(4-methoxy-benzyloxy)-heptan-1-one 
• 325172-42-7 toluene-4-sulfonic acid 2-[3-(tert-butyl-dimethyl-silanyloxy)-5-(4-methoxy-benzyloxy)-1-methoxymethoxy-pentyl]-pent-4-enyl ester 
• 325172-32-5 2-[3-(tert-butyl-dimethyl-silanyloxy)-5-(4-methoxy-benzyloxy)-1-methoxymethoxy-pentyl]-pent-4-en-1-ol 
• 325172-43-8 tert-Butyl-{(1S,3S,4R)-1-[2-(4-methoxy-benzyloxy)-ethyl]-3-methoxymethoxy-4-methyl-hept-6-enyloxy}-dimethyl-silane 
• 325172-40-5 (R)-[1-(4-methoxybenzyloxy)-3-((tert-butyl)dimethylsilyloxy)hex-5-en-3-yloxy]dimethylsilane 
• 325172-30-3 (S)-3-((tert-butyldimethylsilyl)oxy)-5-((4-methoxybenzyl)oxy)pentanal 
• 325172-48-3 2-methoxy-6-(prop-2-enyl)benzoic acid allyl ester 
• 325172-29-0 (3R)-1-[(4-methoxybenzyl)oxy]hex-5-en-3-ol 
• 325172-28-9 2-allyl-6-methoxy-benzoic acid 
• 204846-40-2 2,2-dimethyl-5-(2-propenyl)-4H-1,3-benzodioxin-4-one 

Downstream Products

• 198482-00-7 (+)-Salicylihalamide A 

Relevant academic research and scientific papers

Revision of the absolute configuration of salicylihalamide A through asymmetric total synthesis

A highly E-selective ring-closing metathesis is the key to building the macrocyclic salicylate core of (+)-salicylihalamide A (1). The synthesis results in a reassignment of the absolute configuration of natural (-)-salicylihalamide A (2), a structurally

Asymmetric synthesis of the fully functional macrolide core of salicylihalamide: remote control of olefin geometry during RCM.

A catalysis-based approach to the core region 24 of the antitumor agents salicylihalamides A and B is reported. Key steps are two asymmetric hydrogenations of beta-keto esters 13 and 16 catalyzed by [(R)-BINAP.RuCl(2)](2).NEt(3) and an RCM-based macrocyclization effected by the NHC-containing ruthenium carbene 21. The stereochemical outcome of the latter reaction is controlled by remote substituents on the phenolic OH group of the cyclization precursor 23.